RHOA and neoplasm: Future efforts will prioritize engineering SC-loaded nanoparticle formulations (e.g., PEG-PLGA carriers) [28] to enhance tumor targeting efficiency and mitigate off-tumor RhoA modulation in normal tissues, and further pharmacokinetic optimization and toxicity profiling are warranted to advance this strategy toward clinical trials.